{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:23:26Z","timestamp":1787750606349,"version":"build-2784847793"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"\n Importance<\/jats:title>\n While originally approved for the management of heart failure, hypertension, and edema, spironolactone is commonly used off label in the management of acne, hidradenitis, androgenetic alopecia, and hirsutism. However, spironolactone carries an official warning from the US Food and Drug Administration regarding potential for tumorigenicity.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the pooled occurrence of cancers, in particular breast and prostate cancers, among those who were ever treated with spironolactone.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, Cochrane Library, Embase, and Web of Science were searched from inception through June 11, 2021. The search was restricted to studies in the English language.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Included studies reported the occurrence of cancers in men and women 18 years and older who were exposed to spironolactone.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Two independent reviewers (K.B. and H.H.) selected studies, extracted data, and appraised the risk of bias using the Newcastle-Ottawa Scale. Studies were synthesized using random effects meta-analysis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Cancer occurrence, with a focus on breast and prostate cancers.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Seven studies met eligibility criteria, with sample sizes ranging from 18\u202f035 to 2.3 million and a total population of 4\u202f528\u202f332 individuals (mean age, 62.6-72.0 years; in the studies without stratification by sex, women accounted for 17.2%-54.4%). All studies were considered to be of low risk of bias. No statistically significant association was observed between spironolactone use and risk of breast cancer (risk ratio [RR], 1.04; 95% CI, 0.86-1.22; certainty of evidence very low). There was an association between spironolactone use and decreased risk of prostate cancer (RR, 0.79; 95% CI, 0.68-0.90; certainty of evidence very low). There was no statistically significant association between spironolactone use and risk of ovarian cancer (RR, 1.52; 95% CI, 0.84-2.20; certainty of evidence very low), bladder cancer (RR, 0.89; 95% CI, 0.71-1.07; certainty of evidence very low), kidney cancer (RR, 0.96; 95% CI, 0.85-1.07; certainty of evidence low), gastric cancer (RR, 1.02; 95% CI, 0.80-1.24; certainty of evidence low), or esophageal cancer (RR, 1.09; 95% CI, 0.91-1.27; certainty of evidence low).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review and meta-analysis, spironolactone use was not associated with a substantial increased risk of cancer and was associated with a decreased risk of prostate cancer. However, the certainty of the evidence was low and future studies are needed, including among diverse populations such as younger individuals and those with acne or hirsutism.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2021.5866","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T11:06:42Z","timestamp":1644404802000},"page":"275","source":"Crossref","is-referenced-by-count":47,"title":["Association of Spironolactone Use With Risk of Cancer"],"prefix":"10.1001","volume":"158","author":[{"given":"Kanthi","family":"Bommareddy","sequence":"first","affiliation":[{"name":"University of Miami Miller School of Medicine, Holy Cross Health, Fort Lauderdale, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Hamade","sequence":"additional","affiliation":[{"name":"Department of Medicine, Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Lopez-Olivo","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Wehner","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Tosh","sequence":"additional","affiliation":[{"name":"Schaffer Library of Health Sciences, Albany Medical College, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"CME\/Clinical Review and Education Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi210073r1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone.","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"issue":"8","key":"doi210073r2","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/ced.v45.8","article-title":"Spironolactone in dermatology: uses in acne and beyond.","volume":"45","author":"Searle","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"doi210073r3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamadermatol.2018.4944","article-title":"Trends in oral antibiotic prescription in dermatology, 2008 to 2016.","volume":"155","author":"Barbieri","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi210073r4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jaad.2018.09.055","article-title":"Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments.","volume":"80","author":"Barbieri","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi210073r5","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jaad.2020.12.071","article-title":"Long-term use of spironolactone for acne in women: a case series of 403 patients.","volume":"84","author":"Garg","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi210073r6","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1210\/jc.2009-0345","article-title":"Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.","volume":"94","author":"Hembree","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"doi210073r7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.det.2019.10.006","article-title":"Acne and the Lesbian, Gay, Bisexual, or Transgender Teenager.","volume":"38","author":"Ragmanauskaite","year":"2020","journal-title":"Dermatol Clin"},{"issue":"1","key":"doi210073r8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18773\/austprescr.2019.003","article-title":"Prescribing for transgender patients.","volume":"42","author":"Tomlins","year":"2019","journal-title":"Aust Prescr"},{"issue":"5","key":"doi210073r10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris.","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi210073r11","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone use and the risk of breast and gynecologic cancers.","volume":"37","author":"Biggar","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"doi210073r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"doi210073r13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/bcp.13152","article-title":"Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.","volume":"83","author":"Mackenzie","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"doi210073r14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/120347540200600604","article-title":"Long-term safety of spironolactone in acne: results of an 8-year followup study.","volume":"6","author":"Shaw","year":"2002","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"doi210073r15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrurol.2011.79","article-title":"Differing levels of testosterone and the prostate: a physiological interplay.","volume":"8","author":"Goldenberg","year":"2011","journal-title":"Nat Rev Urol"},{"issue":"n71","key":"doi210073r16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"22","key":"doi210073r17","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2015.15845","article-title":"Prevalence of depression and depressive symptoms among resident physicians: a systematic review and meta-analysis.","volume":"314","author":"Mata","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"doi210073r18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jama.2018.12777","article-title":"Prevalence of burnout among physicians: a systematic review.","volume":"320","author":"Rotenstein","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"doi210073r20","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/s41598-018-19889-8","article-title":"Tissue Factor-bearing MPs and the risk of venous thrombosis in cancer patients: a meta-analysis.","volume":"8","author":"Cui","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"doi210073r21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"doi210073r22","doi-asserted-by":"publisher","first-page":"f7450","DOI":"10.1136\/bmj.f7450","article-title":"Converting an odds ratio to a range of plausible relative risks for better communication of research findings.","volume":"348","author":"Grant","year":"2014","journal-title":"BMJ"},{"issue":"19","key":"doi210073r23","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What\u2019s the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes.","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"key":"doi210073r24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"doi210073r25","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.jid.2016.08.021","article-title":"Research techniques made simple: assessing risk of bias in systematic reviews.","volume":"136","author":"Drucker","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi210073r27","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/ijc.v140.8","article-title":"The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data.","volume":"140","author":"Busby","year":"2017","journal-title":"Int J Cancer"},{"issue":"11","key":"doi210073r28","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00228-019-02740-y","article-title":"Breast cancer and spironolactone: an observational postmarketing study.","volume":"75","author":"Sabatier","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"doi210073r29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/HJH.0000000000001130","article-title":"Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study.","volume":"35","author":"Chuang","year":"2017","journal-title":"J Hypertens"},{"issue":"3","key":"doi210073r30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41391-020-0220-8","article-title":"Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study.","volume":"23","author":"Beckmann","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"doi210073r31","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/bcp.v87.4","article-title":"Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: a pharmacoepidemiological study.","volume":"87","author":"Hiebert","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"doi210073r32","first-page":"672","article-title":"Long-term use of antibiotics and risk of colorectal adenoma.","volume":"67","author":"Cao","year":"2018","journal-title":"Gut"},{"issue":"11","key":"doi210073r33","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1158\/1055-9965.EPI-06-0401","article-title":"Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women.","volume":"15","author":"Friedman","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"doi210073r34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.291.7.827","article-title":"Antibiotic use in relation to the risk of breast cancer.","volume":"291","author":"Velicer","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"doi210073r35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjo.2005.112.issue-7","article-title":"Symptoms associated with diagnosis of ovarian cancer: a systematic review.","volume":"112","author":"Bankhead","year":"2005","journal-title":"BJOG"},{"issue":"4","key":"doi210073r36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study.","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"doi210073r9","year":"2008"},{"key":"doi210073r26","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Page","year":"2021"},{"key":"doi210073r19","unstructured":"Wells? GA, Shea? B, O\u2019Connell? D, . The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute. Accessed December 30, 2021. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2788624\/jamadermatology_bommareddy_2022_oi_210073_1670337725.22877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T11:03:30Z","timestamp":1670411010000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2788624"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.5866","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}